1 Organizing for sustainability success Sustainability Report 2021-22
2 The concern about sustainability has grown into a vital conversation today making it now an essential ingredient for a company’s long-term success. Sustainability is not an add-on, separate from core activities. Organising for Sustainability Success is about making our journey towards sustainable development integrated and impactful. Essentially it is about having a culture of sustainability. It means progressively reducing the knowing-doing gap by proactively addressing sustainability-related material issues. The aspect of competitive advantage drawn from sustainability success is of paramount importance to us. We seek to achieve it by operationalizing sustainability across our entire business. Across the value chain, starting from discovery services to manufacturing, sustainability aspects are upheld by us. We know success is more likely when we empower our teams to engage proactively and strategically align with critical issues such as access to medicines, process safety, environmental performance, and conservation of material resources for creating measurable impact. We are on a continuous journey to maximize the value of our sustainability initiatives and make it meaningful for our stakeholders. Sustainability at Sai Life Sciences
3 The report documents progress and commitment to our Sustainability journey. This is our 3rd sustainability report and we passionately put this report together as an annual feature in our ongoing responsibility to be transparent to our stakeholders on the actions taken and progress made. We present this narrative across the four elements that define our sustainability framework: • Sustaining as a partner of choice • Being an employer of choice • Growing as an HSE champion of choice • Becoming a neighbour of choice Reporting period April 2021 – March 2022 Reporting Cycle We follow an annual cycle for the purpose of this report Scope & Boundary • Corporate office • R&D centre, India • R&D centre, Manchester, UK • Manufacturing facilities in India - Bidar (Unit IV) - Bollaram (Unit III) - Shameerpet (Unit II) Scope of reporting • Financial performance reporting: India, USA & UK • Environmental performance indicators: India & Manchester (only incident statistics) • Employee metrics: India & Manchester • Community updates: India About this report Framework used in the report This report has been developed using the Global Reporting Initiative (GRI) standards: Core option. We have referenced the global Sustainable Development Goals (SDGs) to frame our goals under the sustainability framework. ....................................................................................................................................................................
4 Contents Message from our Chairman 5 6 8 19 28 31 45 57 73 80 87 Message from our CEO About us Sustainability Framework Governance Sustaining as a partner of choice Being an employer of choice Growing as an HSE champion of choice Becoming a neighbour of choice GRI content Index Glossary ........................................................................................................ ........................................................................................... ................................................................................................................. ................................................ .............................................................. ........... ................... ................. .............. .............................................................................. .............................................................................................................
5 Message from our Chairman Dear Stakeholders, We consider ourselves as a value creator in the New Chemical Entity (NCE) discovery, development and commercialisation supply chain. Drug discovery pursuits require nurturing a mindset of trust and collaboration along with a network of talent and expertise. We are immensely proud that we engage in sustainable growth through our contribution to the drug discovery pipeline while partnering with innovator pharma companies, biotechs, start-ups and academic institutions. A significant amount of work is happening globally to improve the ability to predict the clinical success of a drug candidate. Collecting and curating high-quality data across the drug discovery process is creating immense value for humanity. Yet the list of unmet therapeutic needs remains long. The challenges are huge, and despite COVID-19 pandemic-related uncertainties in the reporting period, we moved up the steep curve by investing and embracing new technologies and a wide range of expertise to drive speed and decisively handle complexity. The investment we have made in creating what our global innovator partners expect in their in-house facilities, as part of Sai Nxt, is finding resonance with our customers and partners. I believe that we will continue to make a difference. Starting as a chemistry services provider in 1999, we have now gone well beyond chemistry and have over 60% of our work comprising of integrated services. Our capable team of synthetic and medicinal chemists and biologists have a successful track record of delivering 15 sponsor programs from initial discovery to IND and delivering an impressive 95%+ of all molecules requested. In addition, we have seen a shift towards programs moving out of discovery and into CMC, with outsourcing companies being comfortable with the culture and capability fit of Sai with their organisations. Forging a path through discovery and into development with the same integrated partner where a good relationship, expertise and capabilities exist helps us holistically contribute to meeting unmet patient needs. Sustainability success is a promise as we pursue our growth plans of achieving further scale, scope and speed while consciously integrating our environmental, social and governance responsibilities. I know we have organised our strategy, culture and day-to-day operations keeping sustainability at the core. It is a shared responsibility encompassing all our key stakeholders and my heartfelt appreciation for their commitment and perseverance. I am very excited and look forward to a promising 2022. There could be more challenges and uncertainties. Yet we are unfazed as our endeavours are aligned and drawn from the question “What’s the impact of our actions on the lives of patients and society?” We will always seek to understand patient needs and work with our key stakeholders to bring the best solutions forward. We know that there is a lot to do and we commit to working responsibly year after year, going above and beyond. Sincerely, K Ranga Raju Chairman
6 Dear Stakeholders, Marking the completion of 20 years since our inception, in 2019, we announced Sai Nxt, an organisation-wide initiative aimed at transforming us into a new generation CRO-CDMO and a key player in the value chain which shapes the future of pharma innovation. Envisaged as a 4-year program, it aims to drive transformation across three core areas - People & culture; Processes & automation and Infrastructure & scientific capabilities. One year into the transformation journey, we were confronted by the uncertainties posed by the COVID-19 pandemic. The stakes were high, with a commitment to significantly expand and upgrade R&D and manufacturing facilities, deepen scientific and technological capabilities and the pace intense with the bar raised for safety, quality and customer focus. To sustainably continue our transformation journey, we learned to simultaneously tackle the urgent and the important. We never lost sight of the patient standing to gain at the end of every project. Despite the challenges, we anchored our actions with SaiNxt, exploring options and choices that would be differentiated so that we could face the disruptive challenges of the present and also be future-ready. Navigating the impact of the COVID-19 pandemic increased the pressure on us to urgently manage hybrid teams, reassure employees and ensure business continuity with timely actions in operations and supply chain. However, we also went ahead with our investments in infrastructure and added talent. We opened our new biology facility in our integrated R&D campus in India, unifying discovery, early & late phase development and clinical supply capabilities in a single 13-acre campus. Simultaneously, the four-fold expansion at Alderley Park, UK facility with the state-of-the-art chemistry and analytical laboratory created access to the finest pharmaceutical talent and an ecosystem that nurtures innovation. Another addition included the high potent laboratory facility that makes our infrastructural capabilities meet our customer expectations as more HPAPIs are under development, especially in oncology and orphan indications. We are focussed on integrating the environmental, social, and governance aspects into our strategies and the way we do business. We acknowledge that this is not solely the responsibility of one specific function, but needs to be addressed throughout all operations, and in the supply chain as well. We became a signatory of the United Nations Global Compact (UNGC) to take forward our commitment to implement the ten principles in our operations and sphere of influence. This translated into clear and focused priorities regarding sustainability in business strategy and operations. We as a key player and partner of innovator pharma companies have made sustainability a priority in managing energy, water use, and waste generation. We also collaborate with and monitor our suppliers’ sustainability performance and seek improvements in the efficiency of the transportation networks. We exceeded our sustainability targets in FY 2022 - 18% of the total energy consumption was supported by renewable energy, specific greenhouse gas emissions reduced by 37%, and specific hazardous waste generation reduced by 27% while recycling 86% of hazardous waste through co-processing and alternate reuse. This is our planet and we need to play our part to create Message from our CEO
7 sustainability success by adopting a culture of responsibility. We approach our R&D with a more sustainable mindset. Green chemistry and flow chemistry explorations are key to this, helping our chemists to design reactions and processes with improved efficiency, reduced waste, and lower environmental impact. The combined capacity and competence of our people is the lynchpin of our growth. Over 1200 scientists in our integrated campus in Hyderabad and our facilities in Manchester and Boston augment both our talent and expertise. We have deployed cutting-edge platforms and technology to accelerate and add value to projects in the drug discovery continuum, working effectively as cross-functional teams with seamless communication with our partners. The Women in Science program gives greater emphasis to employment and empowerment of women and the presence of Diversity & Inclusion ambassadors in our facilities drives real progress. The Shopfloor transformation initiative (SFTI) conceived as part of Sai Nxt is continuing to generate sustained improvement in processes and culture which makes our manufacturing team consistently demonstrate the spirit of ownership and collaboration, winning customer confidence and trust. Our commitment to OH&S provides our stakeholders with an assured partnership. We are stepping up our capabilities to build a safer workplace, establish robust management systems, and operational controls, upgrade to state-of-the-art manufacturing facilities/equipment and build process safety capabilities that are on par with international standards. Our undivided attention was towards health and well-being ensuring vaccination of our employees, and their families including contract employees as COVID-19-related challenges continued to impact health. Additionally, our employee wellness initiative with the motto of mind or body, let’s make it better together, creating a robust program on mental health and awareness for all our employees. Another highlight was building bridges and enhancing our relationship with the community through the Champions for Children program besides other continuing initiatives toward health and education. We paired employee volunteers as mentors with students in government-run schools. The mentors provided virtual academic support and served as role models to the children. This was much-needed support for schools to tackle the COVID-19-related impact on education. Our sustainability journey continues to give us new learning and new aspirations. There is much hope on the horizon, there is a lot to be done and we need to focus on the many positive opportunities that lay ahead. We look forward to continued partnership with our key stakeholders. Sincerely, Krishna Kanumuri CEO & Managing Director We undertook an important step “ ” towards strengthening sustainability across our operations by becoming a signatory of the United Nations Global Compact (UNGC). Accordingly, we have committed ourselves to implement the Ten Principles of the UNGC and make them part of our strategy, culture and day-to-day operations. This will also help us accelerate our progress towards our Sustainable Development Goals.
8 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... About us .
9 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Sai Life Sciences is one of India’s fastest growing Contract Research, Development & Manufacturing Organization. As a pure-play, full-service CRO-CDMO, we work with over a 200 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. Today, we have 2200 employees across our facilities in India, UK, USA and Japan and we are headquartered at Hyderabad. Our R&D and manufacturing facilities are built to global standards and cater to an international set of clients. .
10 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Strong global presence Hyderabad London R&D and manufacturing sites Commercial presence ........................... Bidar Manchester Boston Berlin Newcastle Milan Shanghai Tokyo Massachusetts New York North Carolina Indianapolis San Diego San Francisco Ohio .
11 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... CSR contributions 0.3 $ million At a glance Revenue $115.9million Fixed assets $103.4million Profit after tax (PAT) $8.3million We work with innovator pharma and biotech companies to accelerate the discovery, development, and manufacture of complex small molecules for a healthier tomorrow. Our vision is to support our global innovator partners bring 25 new medicines to life by 2025. And we are well on that journey. Our work is built on the firm bedrock of partnership. We are committed to being flexible, responsive, and innovative in addressing the evolving needs of our customers and the environment. Together we better the lives for patients around the world. .
12 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Tox to early phase supplies Commercial supplies Mid to late phase supplies Biology Medicinal & Synthetic chemistry DMPK Toxicology in vivo Pharmacology Discovery Development Manufacturing Computational chemistry Process R&D Analytical R&D Early Phase Scale-up Process Engineering Process Safety Sai Life Sciences has been a trusted partner for pharma companies, biotechs, start-ups and universities, helping them navigate the regulatory and scientific complexities within the drug discovery and development continuum. We employ optimised and tailored solutions that accelerate the drug discovery process, consistently delivering excellence and influencing outcomes. Drug discovery continuum: Our services .
13 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Discovery services spanning the entire journey from target ID and validation to IND Comprehensive range of services We deliver integrated discovery services spanning synthetic and medicinal chemistry, biology, DMPK and toxicology to a global client base across diverse therapeutic areas. Preclinical toxicology Drug substance/Product Med Chem Design Synthesis ADME PK Pre Formulation Biology .
14 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Two global sites delivering integrated value Transfer to India reduces costs and cycle-time • Client & project specific exploratory biology • Target validation, novel assay development, etc. • Proximity to clients facilitaties collaboration & communication • Rapid reagent procurement enables nimble exploratory activities • Additional capabilities for high throughput in vitro assays • In vivo capabilities for PK/PD and efficacy • Co-localized with Synthetic Chemistry, ADME, PK, and Toxicology • Lower cost services Boston Hyderabad .
15 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Chemistry, Manufacturing, and Controls (CMC) For over two decades, we have consistently delivered on a diverse set of NCE development programmes for our customers with a track record of bringing value based on quality, pricing, and responsiveness. With a strong team of scientists and process engineers, we are up to any challenge involving complex chemical synthesis from route scouting, process development, scale-up to commercial scale. Our world-class manufacturing facilities are equipped with flexible and versatile infrastructure, tailored to fit the smaller volume but more complex chemistry coming out of the development pipelines today. We are continuously upgrading ourselves through investments and in pursuit of making it better. Delivering complex chemical synthesis from development to commercial scale Phase specific approach Judicious use of process development and scale up to deliver the projects on-time. Technologies Catalysis (Bio- & Chemo-), Flow chemistry, Particle Formation, Nucleosides & Phosphoramidites. Technology Absorption Team at plant focused on critical process parameter, batch cycle time, scale-up efficiency; works independent of production function to ensure successful transfer of technology from lab to plant. Fully-automated pilot plant Plant-like automation to help understand the process before scale up. Process Engineering PE to R&D team ratio 1 : 5 for developing efficient and scalable processes. .
16 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... SaiNxt: Our transformation engine Guided by the insights and feedback of our customers, we have expanded our R&D and manufacturing facilities, deepened scientific & technological capabilities, strengthened automation and data systems, and raised the bar for safety, quality, and customer focus. People & Culture Expanding scientific talent pool, inducting top-notch global scientific and leadership talent, role-based integrated online training, shop floor transformation, nurturing culture of excellence. Processes & Automation Process simplification, strengthening governance systems, electronic manufacturing records, IT systems integration, foundation for seamless data capture across operations, leveraging latest technologies for innovation and intelligence. What is SaiNxt • An organizational transformation initiative • Investment target of $150 million • Time frame: 2019-2023 • Focus areas: - People & culture - Processes & automation - Infrastructure & scientific capabilities Infrastructure & Capabilities R&D expansion with wider suite of technology platforms, early phase delivery facility, flexible manufacturing with 2.5x capacity, advanced safety & quality systems. .
17 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... New facilities launched since April 2019 Integrated Research and Technology Centre Early Phase Delivery Block Biology Lab & Vivarium Discovery Expansion at R&T Centre Hyderabad, India High Potency Development Lab, Hyderabad High Potency Manufacturing Block 172KL cGMP Manufacturing Clean Room Block Bidar, India Biology Lab Process R&D Lab Boston, USA Manchester, UK .
18 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Our growth Strong pool of scientific talent Awards and recognition R&D 1200 2200 employees Quality 300 Manufacturing 650 100+ clinical stage programs served; 28 active commercial programs & 9 in Phase III USA, EU, Japan > 95% of products manufactured serve these highly regulated markets USFDA, PMDA 100% successful track record of regulatory inspections across our R&D and manufacturing facilities 35+ programs advanced from IND to phase I, II or III Member of > 200 active customers of innovator companies Sai Life Sciences’ API manufacturing unit receives ‘CII Excellent Energy Unit’ award Sai Life Sciences’ wins GSK Environmental Sustainability Supplier award 2021 in the ‘Primary Manufacturing’ category .
19 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Sustainability framework .
20 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... The Sai Way is driven by a belief in our purpose of “Science for a healthier future” and unwavering faith in our promise to “Make it better together”. We maintain a strong commitment to our values and adhere to these two guiding principles. We firmly believe that to stay relevant to our purpose and to translate our intentions into actions, our defined sustainability framework continues to provide us with the direction to conduct responsible business in line with the environment, social and governance practices. We are integrating sustainability into the core of all our business strategies to benefit the bottom line along with creating an impact to a wider stakeholder base. Our Promise Our Purpose .
21 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Science for a healthier future Make it better together Our Values S a i N x t Our Sustainability Framework Sustaining as a Partner of choice Being an Employer of choice Growing as an HSE Champion of choice Becoming a Neighbour of choice World-class infrastructure Advanced technological capabilities Best-of-breed talent Automation & Data systems Safety & Quality focus Environmental consciousness Integrity Respect Transparency Collaboration Ownership Reliability Operational excellence Speed & responsiveness .
22 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Sai’s sustainability framework takes its roots from the UN’s Sustainable Development Goals and was adopted in 2019, with a four-year time frame. The SDGs were identified based on the material areas critical to our stakeholders and paramount to our business. We at Sai understand that as a growing leader in the CDMO segment, to achieve the set targets, we need to foray into new directions to embrace more sustainable and inclusive models. Environmental protection Community Diversity & Inclusion Responsibly supply chain As a part of the UN’s 2030 Agenda for Sustainable Development, the 17 SDGs were designed as goals for governments and a calling to businesses to apply their creativity and innovation in solving sustainable development challenges. .
23 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Exceeded target 18% 37% 27.3% 3.7% 86% 11% 6365 12795 Reduce specific greenhouse gas emissions by 10% In progress Under review Reduce specific hazardous waste generation by 10% Replace 10% of our overall energy requirement with renewable sources Recycle 70% of waste through coprocessing and alternate reuse Increasing percentage of women employees in total workforce by 12% Reduce specific water consumption by 10% Provide education and create livelihoods for 1500 people from financially and socially less privileged communities Free medical screening to 10,000 people through our health care programs Competency profiling and risk assessment for all critical raw material suppliers progress update .
24 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Our holistic approach in HSE areas demonstrates positive progress across the SDG goals on environmental indicators. With changing market dynamics amongst the uncertainties that loomed over the world post-pandemic, we had our share of challenges in meeting these targets. We report minor progress on two of the SDG goals. An increase in production capacities, development of complex molecules, infrastructure expansions, and enhancing capabilities on several initiatives made it challenging to achieve the reduction in water consumption target. We are in the process of reviewing our goals and targets that are yet to be attained and shall re-commit our resources to meet the revised targets. We believe it is our ongoing responsibility to be transparent to our stakeholders about the progress we are making toward achieving these goals. We shall be revisiting the Sustainability framework with continued commitment. We are encouraged that our focus and thrust on making sustainability our way of working is paying off. The awards in multiple areas of sustainability are proof of our continuing pursuits. In the reporting year, we were recognized for our sustainability efforts which shows our commitment and earns the confidence and trust of our key stakeholders. Sai became a signatory of the United Nations Global Compact (UNGC) and committed itself to adopting the Ten Principles of the UNGC on human rights, labour, environment and anti-corruption. Won the Environmental Supplier award 2021 in the ‘Primary Manufacturing’ category for effectively embedding green chemistry principles in its approach to process development. Awarded with ‘Excellent Energy Efficient Unit’ in the general category at CII’s 22nd National Energy Management Awards. This is the second consecutive year that Unit IV,’ Bidar API facility has been awarded by CII for its energy management. Associate member of ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) with a commitment to increase the adoption of Green Chemistry principles in its process development Sai became PSCI’s first member with its main headquarters in India. This step is a strong reaffirmation of our commitment to implement and champion responsible supply chain practices.” Sai retained the Silver rating and increased the overall score from 57 to 63 this year at the Eco Vadis Assessment, in the industry category “manufacture of basic pharmaceutical products and pharmaceutical preparation”. Sustainability Awards and Recognition Sai received LEED GOLD rating from the U.S. Green Buildiing Council for its R&T Centre at Hyderabad. “ We strongly believe that an organisation’s ability to create long-term value rests on its collective execution rhythm each day. We use Strategy Deployment Process to translate breakthrough long-term performance goals into short- and medium-term goals. With this approach, we identify critical processes, capabilities and infrastructure that need to be upgraded to create sustainable improvement in performance. These improvements are measured through lead indicators that give us an insight into how sustainable improvements fuel breakthrough performance improvement. Sauri Gudlavalleti Chief Operating Officer
25 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Materiality Sai conducted the materiality assessment in 2019 and this assessment helped us understand the significant impacts on our business activities, and the impact of our operations on the environment and the societies in which we operate. In the materiality assessment, we made our stakeholders play an integral part in the process to prioritise the different aspects and identified the key material areas. These material areas are addressed under the four key dimensions of our sustainability framework. We integrate material sustainability topics into our sustainability framework and have been periodically reviewing the changing landscape. .
26 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Organizing for sustainability success by integrating sustainability at the core Sustaining as a partner of choice Becoming an employer of choice Growing as an HSE champion of choice Water management Waste management Supplier engagement on EHS Compliance with regulatory, quality, HSE, labor & ethics requirements Operational excellence, sustainable manufacturing, quality, safety, delivery cost efficient Quality of science, robust process design, speed in technology transfer Volunteering Supporting education Infrastructure development for education Energy management Employee Engagement Health Diversity & Inclusion Benefits and Performance management framework Employee development & skill building Process Safety Capabilities OHS The distance of the focus material area from the core of the sustainability framework signifies the extent to which the material area has been integrated into the business. Becoming a neighbour of choice .
27 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Stakeholder Engagement In understanding and prioritizing the organization’s material issues, we acknowledge the part played by our stakeholders in making this process more effective, transparent, accurate and complete. This gave us the window of opportunity to connect, listen and engage with our stakeholders and to improve as an organization through insights on potential business risks and opportunities that can influence our ability to create a positive impact along the value chain. Through stakeholder engagement, we are directing our efforts to maximize the benefits to our stakeholders, our organization, and the planet. Quality, cutting-edge practice in R&D and technology, robust process, On Time In Full delivery (OTIF)partner in meeting environment goals, safe process and workplace, Sustainability performance, goals & targets, Reporting Customers R&D, Technology Transfer, HSE, Manufacturing, Quality, Program management, Operational Excellence Audit, Project review meeting, Customer feedback survey, Business Development Meeting, sustainability survey Meeting career goals, benefits, performance management, skill building, engagement & empowerment, safe workplace HR, R&D, Manufacturing, Operational Excellence Employee satisfaction survey, one on one discussion, departmental meeting, PMS review, SFTI walk throughs, HSE review meetings Employees ESG Performance, Customer engagement, meeting business growth goals, Stakeholderengagement, cost efficiency, OTIF, Right first time Governance, Finance, Business Development, R&D, Manufacturing, HSE, Operational Excellence Board meeting, Management review, Investor meeting, Annual diagnostic survey, ESG forum Investors/Board Suppliers Strategic partnership, support in meeting HSE and Quality goals SCM, Manufacturing Audit, Performance review meeting Community/NGOs New focus area such as mental health, COVID -19 response support, continuing engagement CSR, Manufacturing, HR, R&D Engagement meeting, Volunteering activity Regulators/Government Compliance HSE, Quality, Manufacturing, R&D Audit, Annual review Stakeholder Key expectations Boundary Engagement mechanism Associations Best practices, Knowledge sharing HSE, Quality, HR, Manufacturing, SCM Conference, Events, Award application
28 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Governance .
29 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Strong governance is integral to our organizational success. The Board of Directors at Sai Life Sciences represent the stakeholders and takes responsibility for providing direction to the company, overseeing the implementation of the Board’s decisions and building long-term shareholder value. Board of Directors Dr. K. Ranga Raju Chairman Executive directors Krishna Kanumuri CEO & Managing Director Non-executive directors Raju A Penmasta Director Mitesh Daga Director Rajagopala S Tatta Independent Director Puneet Bhatia Director Nandita Gurjar Independent Director .
30 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... The Board of Directors is the highest governing body and comprises both executive and non-executive members. The strength of the Board of Directors is seven of which the Chairman and Managing Director are the executive members. The nonexecutive members comprise three directors and two independent directors, one of whom is a women director. The board meets a minimum of four times a year to review significant developments affecting the company and to discuss and act on matters requiring Board approval. The Sai Board of Directors oversee the sustainable development positions and related strategic planning, risk management policies and procedures. At the Board level, the Management Committee has the overall responsibility for the management, target setting, performance, and long-term success and sustainability of Sai. Additional Corporate and site-level committees ensure the implementation and tracking of new initiatives as well as the identification of new opportunities. Driving sustainability through the organization is on the agenda of every leadership function at Sai. The Senior Vice President of HSE is the Sustainability executive of the company. He is involved in reviewing the performance of the SDG goals, overseeing the company’s HSE requirements, goals, management systems and operational excellence initiatives to achieve results consistent with the company’s vision. The Board has constituted six Board committees for effective decision-making and has a systemic process for managing and delegating authority in several aspects. These committees focus effectively on issues and ensure expedient resolution of diverse matters. The Board delegates certain elements of its oversight functions to one or more of its committees. Each committee convenes at least quarterly. At Sai, we seek director candidates who possess the highest personal and professional ethics, integrity, and values and who are committed to representing the long-term interests of all Sai’s stakeholders. • Audit committee • Securityholders relationship/ investors grievance committee • Independent directors committee • Nomination & remuneration committee • Corporate social responsibility (CSR) committee • Vigil mechanism committee .
31 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Sustaining as a partner of choice .
32 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... We are continually organizing for sustainability success and making a tangible difference in how big pharma and biotech companies meet patient unmet needs as part of their sustainability contribution. Over the past two decades, the CDMO sector has greatly advanced and is now considered an integral source of drug development and delivery. For us being integral translates into a partnership credo andhigher responsibility for committedly delivering as part of the innovation value chain. It is about being more than just a “pair of hands” but instead trusted collaborators enhancing the potential for innovative new drugs reaching patients while meeting sustainability goals. 1. Working across a diverse set of therapeutic areas, the Integrated Discovery Services team is seeking a sustainable footprint by contributing to patient-centricity The backbone of our service culture success is - reliability, consistency in team capability and communication helping us to productively deliver novel chemistry, in a faster time, with efficient iterations for the final molecule to be chosen. Sai’s Discovery services business has doubled its scientific resource pool and tripled its laboratory space for Medchem and this offers a flexible approach to fulfilling the Full-Time Equivalent (FTE) model. We are handling the development of complex, cyclic peptides conjugatedwithlinkersamongotherchemistrycapabilities.Asimilarexpansionofpeopleresourcesand laboratory space has been done for Biology in our facilities in Cambridge, Boston and in Hyderabad, India. Our growing capabilities in Electrophysiology, high content imaging and Eco dispensing systems in the Biology services space are pivotal to our client engagement. Integrated discovery services A strong track record of enduring customer relationships averaging 10+ years. which includes big pharma, mid-sized pharma, biotech’s, and startup companies including oncology, pain, inflammation, fibrosis, CNS, autoimmune and rare diseases among others Supported over 180+ discovery programs for a global clientele 18 months average turnaround time from Hit/Lead to Candidate 35+ programs advanced to different clinical phases (IND to Phase-III) Multiple therapeutic areas
33 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... High Content Screening (HCS) Assays at the forefront A Powerful Approach to Systems Cell Biology and Phenotypic Drug Discovery HCS provides data specifically at the target site, as well as any off-target effects, all in the same assay. We have developed wide range of assays starting from simple downstream marker modulations like nuclear translocation, cytosol to plasma membrane translocation, post translational modifications to complex autophagy, mitochondrial morphology/fragmentation, RNA/protein aggregate formation, cell shape/morphology, target distribution changes and neurite outgrowth assays over a period of 3 years in 384 well format. .
34 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Services for academic institutions and start-ups Our work is part of a collaborative ecosystem seeking to contribute to more successful academic pharma. Their focus on discovering new chemical entities for rare diseases either first in class or best in class drug candidates, is supported by our parternship. The nature of our work can potentially support their presence in the development to the market value chain by engaging with pharmaceutical companies which help them further with their discoveries. For over 10 years we have provided standalone services (chemistry and DMPK or standalone chemistry or standalone DMPK) to support startups, virtual groups, and academicians to achieve drug discovery and development projects. We continue to add infrastructure to enable academicians and support the project goals through exploratory studies in the areas of CNS drug discovery, PROTAC modalities, Antibody-drug conjugates, and prodrug research. As per the National Centre for Biotechnology Information, US, in 2021, 75% of the drugs accepted by the FDA were small molecules, with the dominant therapeutic area being oncology. Over 50% of these approvals were from small and mid-sized companies which require support from CDMOs for the commercialization of products. We are guided in our sustainability success as we align with our customer expectations In the current environment, we are continuously adapting our offerings and capabilities to suit the evolving requirements of our existing and prospective partners and to meet their expectations by undertaking critical moves such as: 1. Increasing process development capabilities--securing access to high containment synthesis 2. Developing capabilities in particle engineering 3. Exploring the potential of continuous processes 4. Adapting the production capacity for flexibility Accelerating development timelines Speed Scientific Excellence Environmental & Safety Risk Management Meeting Technical Needs Proactively meet process development demands Anticipating potential risks and avoiding potential liabilities by using the precautionary principle Developing APIs to suit the needs of bioequivalence and ease of formulation Addressing sustainability related queries in RFP/RFQ covering policies, external certifications, ratings, environment metrics etc. Efforts towards net zero in the value chain by taking action on reducing the Scope 1, 2, 3 emissions Report on environmental metrics and engage for performance improvement Assessment on EcoVadis platform and successful PSCI audits covering topics of Environment, Health & safety, Human rights & labour & ethics 2. Growing value-added strategic services in the CDMO space that help create a positive “customer experience” Our partnership credo has sustainability inbuilt for mutual success and growth. Critical sustainability expectations
RkJQdWJsaXNoZXIy MTIwMDc4NQ==